Intrasense Sa · EURONEXT:ALINS
Intrasense Sa — Investor Presentation (May 2021)
28 slides from Intrasense Sa's investor presentation, May 2021
Slide 1: Investors presentation
Investors presentation Leveraging medical imaging for patient care May 2021 intrasense.fr
Slide 2: Disclaimer
DISCLAIMER This presentation (the “Presentation") has been prepared by Intrasense solely for information purposes The provision of this Presentation (i) does not place the Company nor any of its directors, based on publicly available information and information supplied by the Company’s management f
Slide 3: Medical Imaging
Medical Imaging In developed countries, in average each and every one gets 1 or 2 medical imaging exams per year 3 intrasense.fr Source: OECD data 2019 https://data.oecd.org
Slide 4: An experienced and skilled executive team
An experienced and skilled executive team Lionel SELTZ Nicolas REYMOND Chief Financial Officer Chief Executive Officer Post-Graduate in International Business from Strasbourg Msc / Engineering degree from INPT-ENSEEIHT University - MBA Bath University 2016 2020 Khalil FILALI Chief Business Officer C
Slide 5: Strong assets and validated growth path
Strong assets and validated growth path Validated turnaround and ambitious growth strategy 2021 - 2025 Growth and acceleration • New product line • Innovation investments • Europe and China business growth • SaaS offer • New business model for recurring revenue 2018 - 2020 Setting up a new strategy
Slide 6: Company competitive advantages
Company competitive advantages Unique positioning in the Medtech Industry MeVis Original Equipment Pure software Manufacturers players 6 intrasense.fr
Slide 7: Company competitive advantages
Company competitive advantages Unique positioning in the Medtech Industry Integration & Independency ▪ Multi-modality platform, equipment vendor agnostic ▪ OEM & key industrial players partnerships Clinical expertise ▪ Clinical team and partnerships ▪ Set of high-end clinical applications Innovation
Slide 8: Intrasense in a nutshell
Intrasense in a nutshell Technical and regulatory expertise and assets Key figures Medical Device clearance in 40 countries • €12m cumulated R&D investment RZN • 30% revenue reinvested in R&D CE Mark • 170 scientific publications FDA • 3 international patents Class IIa CFDA • ISO 13485 standard ICME
Slide 9: Intrasense in a nutshell
Intrasense in a nutshell Expanding a loyal customer base Customer satisfaction as key focus Worldwide hospital references • Customer satisfaction* on products and services: 4.4 / 5 • Customer recommendation* to peers : 4.5 / 5 • Average maintenance contract duration : 4 years * based on 2020 annual
Slide 10: Company figures for 2020
Company figures for 2020 Completed turnaround with operational breakeven France RoW 17% 7% China Europe* 40% 36% * Including Russia 10 intrasense.fr
Slide 11: Medical Imaging Software market on the rise
Medical Imaging Software market on the rise Driven by unmet clinicians needs and increasing demand S4H Radiologist workflow under pressure Fostering transformative innovations 120- More effective diagnosis and better patient outcomes 200 26% Due to fast 3–5 Risk speed ✓Greater precision Reports/day/
Slide 12: Medical Imaging Software market on the rise
Medical Imaging Software market on the rise A growing $1.5bn market, expected to double by 2024 $3bn addressable market in 2024 Dynamic across all regions $ bn 1,5 +4%* Americas EMEA Asia 1 + 16%* + 13%* + 12%* +34%* 0,9 $0,9 0,5 bn bn$ 1,3 $1,3 bn$ bn 0,7 $0,7 bn$ bn 0 2019 2024 Advanced Visualizat
Slide 13: Financing tomorrow's growth – From Myrian to Myra
Financing tomorrow's growth – From Myrian to Myra - Built on solid fundamentals to deploy an ambitious strategy Introducing an innovative and complementary new offer Myra Oncology Board – Disruptive new offer Innovation Marketing Go-to-market Talents for strengthening R&D team Strong brand awareness
Slide 14: Intrasense solutions
Intrasense solutions Introducing an innovative and complementary new offer Since 2006 - Myrian platform 2021 and further - Myra Oncology Board Disruptive new offer Multimodal Advanced visualization solution aiming at providing radiologists with cutting Patient centric oncology solution, report drive
Slide 15: Myrian advanced visualization platform
Myrian advanced visualization platform A full toolbox addressing global needs in radiology Value proposition • Medical imaging visualization and processing platform Imaging exam used for radiology screening, diagnosis and pathology follow-up & • Set of 15 clinical applications targeting specific org
Slide 16: Myrian advanced visualization platform
Myrian advanced visualization platform Strong and validated company asset Business model and targets Offer packaging and pricing • One off license payment per module • Average selling price / installation: €30k - €60k • Maintenance contracts: 15% initial price/year (including support and upgrades) D
Slide 17: Myra – Oncology Board
Myra – Oncology Board Disruptive Value Proposition focusing on Oncology Value proposition validated by Key Opinion Leaders • Introducing a layer of intelligence orchestrating the workflow according to the patient context and clinician needs • Automatically providing the right tool at the right time
Slide 18: Myra – Oncology Board
Myra – Oncology Board A patient focused medical imaging solution PATIENT ONCOLOGY CARE PATH Screening Diagnosis Staging Therapy Follow-up Pluri-disciplinary care team Exams, prescriptions & reports PATIENT Smart workflow orchestration AI medical imaging Imaging biomarkers Dedicated Therapeutic respo
Slide 19: Myra – Answering client unmet needs
Myra – Answering client unmet needs Validated market fit Backed by KOLs and clients Blind Interviews with 30 KOL and clients in EMEA and China to: • Confirm pains and pain relievers • Test desirability of innovation concept and willingness to pay Yet, no existing solution on the market • Large playe
Slide 20: Myra – Oncology Assistant
Myra – Oncology Assistant Targeted customer segments generating recurring revenue 1st Release Offer packaging and pricing • Annual license subscription per user, including maintenance • Average selling price per installation: €80k/year June 2022 • Added value services: activity dashboard… • Data val
Slide 21: Myra - Market creation & value generation
Myra - Market creation & value generation Targeted customers generating recurring revenue Amongst 3 065 hospitals in France, 865* public hospitals or private clinics have an authorization to take in charge cancer patients. • Largest centers: CHU (32), CLCC (18), large CH (~150) & large clinics (~100
Slide 22: Intrasense solutions
Intrasense solutions Innovative and complementary offers Myrian platform Myra Oncology Board Advanced visualization solution New product innovation • Cutting edge clinical tools • AI orchestration & smart workflow • Exam centric (organs & modality) • Patient centric (across care path) • Radiologist
Slide 23: Company newsflow
Company newsflow Commentaires oraux et Annexes 2021 2022 2023 2024 2025 2026 Innovation R&D hiring Myra V1 Myra V2 Myra V3 Myra V4 Strengthening R&D team Myrian V2.10 Myrian V3.0 Myrian V3.1 Myrian V3.2 Cloud / SaaS infrastructure AI Hub release Marketing Sites Collaboration agreements China marketi
Slide 24: 5-year organic growth guidance
5-year organic growth guidance Ambitious growth driven by the new product line and targeted regions 24 intrasense.fr
Slide 25: Use of proceeds
Use of proceeds Investing in innovation and go-to-market Key focuses Innovation 12% Talent sourcing for strengthening R&D team Cloud / SaaS infrastructure 28% Marketing Strong brand awareness campaign 13% Total KOL strategic partnerships €4.9m Go-to-market 47% Sales teams growth New market launch (G
Slide 26: Indicative deal structure & timeline
Indicative deal structure & timeline Offer size € 4.9m Offer type Capital increase Pricing € 0.7 Shares issued 6 961 647 shares Parity 2 new shares for every 7 existing shares held May 24th Announcement of the Transaction May 28th Opening of subscription period Timeline June 15th End of subscription
Slide 27: Key investment highlights
Key investment highlights An ambitious and realistic project • A company growth path building on strong historical and proven assets: ✓ Since 2018, thoroughly transformed the group to bring it to operational profitability and prepared the next growth phase ✓ An agile company, with a strong capabilit
Slide 28: Thank you for your attention
Thank you for your attention Intrasense www.intrasense.fr May 2021